FMP
Petros Pharmaceuticals, Inc.
PTPI
NASDAQ
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
0.64 USD
-0.0024 (-0.375%)
About
ceo
Mr. John David Shulman
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.petrospharma.com
exchange
NASDAQ
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
CIK
0001815903
ISIN
US71678J2096
CUSIP
71678J100
Address
1185 Avenue of the Americas
Phone
973-242-0005
Country
US
Employee
21
IPO Date
Dec 2, 2020
Summary
CIK
0001815903
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
71678J100
ISIN
US71678J2096
Country
US
Price
0.64
Beta
2.24
Volume Avg.
985k
Market Cap
4.4M
Shares
-
52-Week
0.602-5.24
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.1
P/B
-
Website
https://www.petrospharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PTPI News
It looks like there's no news available.
